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Abstract Ovarian cancer is the most aggressive gyne-
cologic malignancy, with a 5-year survival rate ranging
around 40 %. A crucial factor influencing the prognosis is
early detection of a suspicious mass and referral to a
gynecologic oncology center for further diagnosis, staging
and debulking surgery. Here, we present the different
imaging methods ultrasound (US), magnetic resonance
imaging, computer tomography (CT) and 18F-fluoro-
deoxyglucose positron emission tomography (PET)/CT
that are used for the characterization, diagnosis, staging
and surveillance of ovarian cancer. In this review, we focus
on US and discuss in detail the advantages and the limi-
tations, as well as the appropriate indications for each of
the individual imaging techniques.
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Introduction
Ovarian cancer is the fifth most common gynecological
cancer. It is the most aggressive gynecologic malignancy,
with a 5-year survival rate of *40 %. In Europe, *41900
women are diagnosed with ovarian cancer and 29200
women die from this disease each year. Over 90 % of the
cancers occur sporadically, mainly in postmenopausal
women [1], although recent evidence suggests that serous
ovarian cancer might be hereditary in up to 44 % of cases
[2].
Despite advances in surgery, chemotherapy and
intensive ongoing research, survival has not significantly
increased. The most important factor for survival is the
disease stage at diagnosis. About two-thirds of the
patients are diagnosed with advanced disease, which may
explain the low-survival rate. When the disease is diag-
nosed at FIGO stage I, the 5-year survival is around
90 %. One reason for the late detection of ovarian cancer
is its asymptomatic nature until later stages and its
location deep in the pelvis. It is often not detected
during the general clinical examinations, and careful
gynecological assessments are crucial.
Once a suspicious mass is detected, an important factor
influencing the prognosis of ovarian cancer patients is the
referral to a gynecologic oncology center for further
diagnosis/staging, debulking surgery and interdisciplinary
tumor board evaluations [3–5].
Diagnostic imaging has challenges and functions in
the detection, staging, preoperative planning and sur-
veillance after initial therapy. Each of the available
imaging techniques for assessment of ovarian cancer
such as ultrasound (US), computed tomography (CT),
magnetic resonance imaging (MRI) and positron emis-
sion tomography (PET)/CT has its special advantages
and limitations. Our goal was to present and evaluate the
different imaging techniques and their role in the char-
acterization of ovarian cancer.
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Diagnosing ovarian cancer
The role of US in the characterization of complex
ovarian masses
The most widely available technique for imaging of the
pelvic organs is transvaginal sonography. It has various
clinical indications and is used in every day practice to
further evaluate pain, irregular bleeding and many other
gynecological symptoms. With transvaginal US, most
adnexal masses can be identified, many of which are
incidental findings. Since ovarian tumors have a wide
morphological spectrum and vary highly in appearance and
in the degree of malignancy, an accurate systematic
approach is important [6]. Benign ovarian lesions are more
common than carcinoma, and for this much larger, non-
malignant group, it is important to reduce unnecessary
interventions without putting the patient at risk for
advanced stage disease. In a recent study exploring the risk
of malignancy in a screening program in postmenopausal
women, as many as 9 % presented with an adnexal mass
[7]. Many different factors can be used to discriminate
between benign and malignant adnexal lesions. These
include personal and family history, including menopausal
status, clinical examination, tumor markers (CA125, HE4),
and most importantly, a wide range of different morpho-
logical US features (Table 1). Among these US features are
the maximal diameter of the adnexal lesion, the presence of
ascites, the presence of solid and cystic components and
the maximal diameter of any solid components. Further-
more, irregular and smooth cyst walls, the presence of
complete and incomplete septa, unilocular and multilocular
cysts and the presence of acoustic shadows are used to
describe the morphology of a lesion. Doppler US is used to
assess the blood flow within a papillary structure and the
color score of intra-tumoral blood flow [8]. Table 1 pre-
sents simple US characteristics developed by the Interna-
tional Ovarian Tumor Analysis (IOTA) group. These
simple rules can be used to characterize adnexal masses as
benign or malignant, and can be used as a triage test.
Further evaluation through an expert sonographer is nec-
essary in cases of unclassified lesions [9].
More than 90 different prediction models to estimate the
risk for malignancy based on the above mentioned features
have been developed, but only very few have been con-
firmed in external validations [10]. The British Royal
College of Obstetricians and Gynaecologists (RCOG) has
published a guideline for the evaluation of an adnexal
finding in postmenopausal women which includes an
algorithm to distinguish between benign and malignant
adnexal masses. The RCOG recommends calculating the
risk of malignancy index (RMI) [11] to decide how to
triage the patients according to the score. The RMI has
reported and validated sensitivities of 78–85 % and spec-
ificities ranging from 77 to 97 % [10–12]. The RMI is a
numeric score that takes into account the CA125 level in
the serum (kU/l), menopausal status (premenopausal = 1,
postmenopausal = 3) and morphologic US score with one
point for the presence of any of the following character-
istics: multilocularity, evidence of solid components, evi-
dence of metastasis, presence of ascites and presence of
bilateral lesions. The RMI is calculated according to the
following formula: U (US features) 9 M (menopausal
status) 9 absolute CA125 value.
For more than a decade, the IOTA group has been
working on developing algorithms to calculate the risk of
malignancy for adnexal masses based on clinical infor-
mation and US features. The idea was to design algorithms
that could be used by non-expert sonographers. Many
studies on the performance of these algorithms have been
published [6, 13–15]. In a recent study from 2012, Van
Calster et al. [16] compared the IOTA model LR 2 to the
current RCOG guidelines and found that the IOTA protocol
was superior to the RMI-based RCOG model. According to
IOTA estimates, more women would undergo minimally
invasive surgery for appropriate reasons, while most
invasive cancers would still be correctly referred to a
gynecologic oncologist. The main limitation to this study,
however, is the fact that experienced sonographers per-
formed all US examinations. As pattern recognition by
gray-scale US through an expert sonographer has a sensi-
tivity of 83 % and a specificity of around 90 %, it is still
superior to all of the known other models developed by the
IOTA group and also presumably better than RMI [14].
Another study by the same group reported on the perfor-
mance of 11 IOTA and non-IOTA models and found that
the IOTA models were better in detecting stage I disease,
with the best performance in premenopausal women [15].
Whether or not these studies will change the current
guidelines remains to be seen.
In addition to US evaluation, new tumor markers have
been introduced into clinical practice, the most promising
of these being human epididymis protein 4 (HE4). A new
algorithm based on the serum markers CA125 and HE4 and
menopausal status without US was introduced as the risk of
ovarian malignancy algorithm (ROMA) [17]. Although
HE4 seems to be effective as a second-line screening
marker and has similar performance as CA125, the cost
benefit of ROMA and HE4 alone and its routine use in
clinical practice are controversial and the right indication
for its use remains to be found [18–20].
It is important to remember that all of the US models
were created after the decision for surgery had already been
made, and there is no information on the outcome of the
patients that had been triaged for expectant management.
Since benign findings are very common, a model
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developed to triage women either to expectant management
or to surgical management is the most important question
remaining [21]. We hope to find answers from another
large study from the IOTA group studying the long-term
behavior of expectantly managed adnexal pathology in the
near future.
At the moment, the preoperative diagnosis of malig-
nancy in persistent adnexal masses by transvaginal US
remains a descriptive approach, yet there is no evidence
that any other imaging modality performs better than US
for this purpose [21]. Due to its ability to image the ovaries
in close proximity, transvaginal US gives the most detailed
Table 1 Simple ultrasound based features for the diagnosis of ovarian cancer according to IOTA [9]
Ultrasound features suggestive of benignity and malignancy adapted from Timmerman [9]
Malignant features (M-features) Benign features (B-features)
Irregular solid tumor Unilocular
Presence of ascites
Presence of a solid 
component, largest 
solid component has a 
diameter of 7 mm
> 4 papillary structures
Presence of acoustic 
shadows
Irregular multilocular solid 
tumor with largest diameter > 
100 mm
Smooth multilocular 
tumor with largest 
diameter < 100 mm
Increased blood flow No blood flow
One or more M-features  in the 
absence of a B-feature, the mass is 
classified as malignant
Referral to gynecologic oncology 
center
If one or more B-features apply in 
the absence of an M-feature, the 
mass is classified as benign 
Conservative management or 
referral to a general gynecologist
If both M- and B-features apply or  
no features are present, the mass 
cannot be classified
Referral to  expert sonographer for 
further evaluation
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information on the internal structure of ovarian masses
(Table 1).
As far as screening for ovarian cancer by transvaginal
ultrasound is concerned, evidence from large randomized
trials could not demonstrate improved survival in asymp-
tomatic women [22]. However, for women with a high
genetic risk for ovarian cancer, transvaginal ultrasonogra-
phy every 6 months and CA125 measurements are rec-
ommended by the National Comprehensive Cancer
Network although evidence for this strategy is lacking.
Results from the UK familial ovarian cancer study intended
to answer this question will be available in 2014 [23].
As transvaginal US is a comparably inexpensive imag-
ing method and is readily available in nearly every gyne-
cological unit, it remains the initial and most important
imaging method for the detection of adnexal masses and
thus for the detection of ovarian cancer.
The role of other imaging methods in characterizing
adnexal masses
Magnetic resonance imaging is now considered as a reliable
tool for the evaluation of gynecological conditions. It can be
used for diagnosis of adnexal lesions and for tumor staging. If
a lesion cannot be sufficiently classified by US, conventional
and contrast material-enhanced MR imaging can help to
determine certain morphological features of the adnexal
mass. MRI can differentiate fat, blood and fibrous content
based on the signal characteristics of adnexal masses. Con-
ventional MR imaging sequences include T1, T2 and fat
suppressed T1-weighted images. Certain findings charac-
teristic for benign lesions include high signal intensity on T1-
weighted images and low signal intensity on T2-weighted
images. Malignant morphologic features include the pre-
sence of solid and cystic areas within a mass, necrosis within
a solid lesion, septations, irregular septa, thickened septa-
tions, ascites, peritoneal disease, lymphadenopathy and
bilateral lesions. Diffusion-weighted imaging has a limited
but useful role in evaluating adnexal masses. Adnexal mas-
ses with a hypointense solid area on both diffusion-weighted
and T2-weighted images are more likely to be benign,
whereas those that are hyperintense on diffusion-weighted
images with intermediate signal intensity on T2-weighted
images are more likely to be malignant [24].
A recent meta-analysis of 22 studies on the performance
of MRI in diagnosing adnexal masses found an overall
sensitivity of 91.9 % and a specificity of 88.4 % (Table 2)
[25].
Another meta-analysis analyzed the value of CT,
Doppler US and MRI as assessment models in cases
where US was inconclusive. They showed that MR
imaging is preferable to combined gray-scale and
Doppler US and to CT for the diagnosis of ovarian
cancer [27]. CT has lower soft tissue contrast compared
to MRI and, therefore, has not been widely used to
differentiate benign from malignant lesions [28]. Early
stages of ovarian cancer can be missed by CT imaging
[29]. Although CT is widely used in ovarian cancer, its
role lies in disease staging rather than in determining the
nature of an adnexal mass, and the reported sensitivities
are lower than for US and MRI (Tables 2, 3). In the last
decade, the introduction of 18F-fluoro-deoxyglucose PET
(18F-FDG PET) has changed diagnostic imaging in
gynecologic oncology. This technique is based on
‘‘functional’’ imaging which makes use of the biologic
characteristics of tumor cells. The elevated glucose
metabolism in most tumor cells causes increased accu-
mulation of FDG (a glucose analog). This radiopharma-
ceutical molecule competes with glucose for transport
into the cell. FDG is a good radiotracer and is signifi-
cantly increased in tumor cells; however, it is not spe-
cific for malignancy [30]. Physiological uptake into the
ovaries and uterus during certain phases of the menstrual
cycle is normal [31–33]. The introduction of combined
FDG-PET/CT scanners allows accurate anatomic defini-
tion of areas of increased FDG uptake and, therefore,
enables improved differentiation between benign and
malignant lesions. Combined FDG-PET/CT scanners are,
therefore, being considered a potentially useful tool for
the characterization of adnexal masses. Only very few
studies have been published so far regarding this subject
and have shown high sensitivities but also high proba-
bilities of producing false negative results in cases of
borderline tumors, low-grade tumors, and early adeno-
carcinomas (Table 2) [34–36]. Although this technique is
promising, it does not give enough additional informa-
tion in the characterization of adnexal masses compared
to US and is not widely available. Furthermore, the costs
of such an examination are higher than those of US, CT
and MRI (Table 3).
Table 2 Reported quality of imaging methods for classifying an
adnexal mass
Sensitivity
(%)
Specificity
(%)
Citation
Ultrasound (US) 96.0 90.0 Timmerman
et al. [25]
Computer tomography
(CT)
87.2 84.0 Dodge et al.
[26]
Magnetic resonance
imaging (MRI)
91.9 88.4 Dodge et al.
[26]
18F-fluoro-deoxyglucose
positron emission
tomography/CT (FDG-
PET/CT)
97.9 73.3 Nam et al.
[37]
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Preoperative staging of ovarian cancer and assessment
of operability
At present, surgical staging remains the gold standard for
staging ovarian cancer and cannot be replaced by any of the
available imaging techniques. However, most gynecological
oncological surgeons request a detailed US by a specialist or
cross-sectional imaging before the surgery to plan staging
laparotomy. The goal is to optimize information regarding
the patient’s situation prior to surgery, to estimate the dura-
tion and extent of the laparotomy and to prepare for/prevent
associated morbidity. Since neoadjuvant chemotherapy prior
to debulking surgery has shown similar results to primary
staging laparotomy in advanced ovarian cancer [38], one can
speculate that the role of staging will become even more
important in the future if treatment options based on diag-
nostic imaging can be discussed. The staging of ovarian
cancer involves the assessment of the local tumor extent (for
example, involvement of the pelvic ureter or uterus), the
presence of peritoneal tumor deposits on bowel and mesen-
tery, the description of unusual disease patterns that suggest
non-ovarian cancer, and the presence of metastasis to lymph
nodes, omentum, liver, spleen and distant metastasis. Stag-
ing requires, at a minimum, the complete assessment of the
abdomen and pelvis [39].
The role of US in staging and assessment of operability
and surveillance after initial therapy
Over the last decade, there have been massive improve-
ments made regarding US techniques. It is a commonly
available, non-invasive and comparatively inexpensive
imaging method that can be carried out without any risk or
discomfort for the patient. If performed by an experienced
sonographer, it has an invaluable role not only in the pri-
mary diagnosis of gynecological cancers but also in the
assessment of tumor extent in the pelvic and abdominal
cavity and in the evaluation of treatment effect and follow-
up [40]. In particular, the issue of cost has led some cli-
nicians and sonographers to re-analyze the diagnostic
capability of US in the evaluation of tumor staging [41].
Fischerova et al. [42] analyzed the ability of US to predict
operability in ovarian cancer cases. They showed that using
US criteria of operability to indicate the use of neoadjuvant
chemotherapy prior to surgery in advanced ovarian cancer
patients significantly increased the rate of optimal surgical
cytoreduction [42]. US has the advantage to be a dynamic
and interactive exam that can provide site-specific tender-
ness and can provide information how pelvic structures
move in relation to each other [41]. Although other
imaging techniques play a more prominent role in staging
and follow-up in most Western countries where CT is
widely available, US can provide important morphologic
information that cannot be assessed by any other imaging
method. One example is the morphological characteriza-
tion of enlarged lymph nodes. While MRI and CT diagnose
infiltrated lymph nodes mainly based on their size, US can
differentiate metastatic from reactive lymph nodes based
on sonomorphological and vascular patterns [41]. A recent
publication on this topic illustrates how US can answer
almost any specific question regarding disease extent if the
patient is scanned systematically and thoroughly with
Table 3 Comparison of different imaging methods for application in ovarian cancer patients
US CT MRI PET/CT
Costs (approx.) 19 29 49 69
Availability Universal Most hospitals Specialized centers, such as
university hospitals
Specialized centers, such as
university hospitals
Main use in
ovarian cancer
Detection and
classification of
adnexal masses
Staging and recurrence If mass unclassified by
ultrasound, if contraindication
for CT
Undefined recurrent disease
(?)
Radiation
exposure
None 10–30 mSv None 10–30 mSv
Exam duration
(approx.
minutes)
20 1 30 30 (?60 min rest)
Use of intravenous
contrast agents
None Iodine-based Gadolinium-based FDG-Radiotracer
Preparation before
imaging
Empty bladder None None 4 h fasting physical rest
60 min
Limitations for
application
None Renal insufficiency,
hyperthyroidism, iodine
allergy
Claustrophobia, cardiac
pacemaker, metallic implants
Renal insufficiency,
hyperthyroidism iodine
allergy
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transabdominal, transvaginal, and transrectal US probes
[40].
One clear indication for US in the surveillance and
diagnosis of recurrent disease involves conservatively
managed ovarian borderline tumors. In these cases, trans-
vaginal US was the most important imaging tool to detect
recurrence in routine long-term follow-up programs [43,
44].
The role of other imaging methods in staging
and assessing operability and surveillance after initial
therapy
At present, contrast-enhanced CT is the most important and
standard imaging method for preoperative evaluation and
postoperative surveillance of ovarian cancer [45]. It is used
to evaluate local tumor extent, operability and recurrence.
In the literature, staging accuracy of CT ranges from 53 to
92 %, compared to 78–88 % for MRI [46–48]. Although
MRI has certain advantages over CT, such as higher soft
tissue contrast and no radiation exposure for the patients,
its applicability is limited because the use of intraluminal
gastrointestinal contrast agents with MRI is not as routine
as with CT (Table 3). MRI is generally more expensive
than CT, and patient motion can be a significant problem
with MRI. However, MRI is recommended for patients
with a contraindication for the use of iodinated contrast
agents, pregnant patients, patients of childbearing age with
borderline tumors (to minimize ionizing radiation expo-
sure) and patients with inconclusive CT findings (Table 3)
[45]. One of the limitations of CT is that the sensitivity of
detecting implants of \1 cm diameter is only 25–50 %
[49].
FDG-PET/CT is increasingly being used as an addi-
tional imaging method for initial staging, but also more
importantly for the surveillance and the detection of
recurrent disease [50]. Recent studies have demonstrated a
benefit compared to CT in the detection of recurrent dis-
ease [35, 51]. In combination with CA125, the detection
rates for recurrence with FDG-PET/CT have been shown to
be as high as 97.8 % [52]. If recurrent disease is present,
FDG-PET/CT is helpful in optimizing the selection of
patients for site-specific treatment, including radiation
treatment planning, and aided in the selection of optimal
surgical candidates [53]. Since ovarian cancer has a rela-
tively high risk of recurrence, PET-CT might become a
relevant tool in the follow-up of ovarian cancer patients.
Conclusion
US is the method of choice for the initial evaluation of
an adnexal mass, estimating the risk of malignancy and
determining its site of origin. It is the only widely
available, inexpensive and risk-free imaging technique
that can give tissue-specific information in relation to
each other and offer such high morphological differen-
tiation. Its role in surveillance is limited but feasible in
the hand of an experienced sonographer. It remains the
method of choice for detecting disease recurrence in
conservatively managed borderline ovarian tumors. We
hope to find evidence for the benefit of ultrasound as a
screening tool for ovarian cancer in high-risk women in
the near future.
CT scan is the standard for preoperative staging of
ovarian cancer but is limited in detecting metastatic
lesions smaller than 1 cm in diameter and is also known
to underestimate tumor stage. It is the standard imaging
method for detecting recurrent disease. MRI can give
important additional information in the characterization
of adnexal masses that cannot be classified with ultra-
sound alone and is an equivalent alternative to CT in
defining tumor stage and detecting recurrent disease. It is
used especially in patients that have contraindications for
CT.
FDG-PET/CT is the newest of the described imaging
methods, which combines metabolic and anatomic imag-
ing. It shows promising results not only as an additional
method in disease staging but also in the detection of
recurrent disease. Its role in ovarian cancer imaging
remains to be defined.
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